Dormant
SLS · SELLAS Life Sciences Group, Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on the last session; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Resolved Graded and closed 2026-09-18 at low conviction — the published kill line fired. Coverage continued after the close; the read below is dated 2026-09-20 and is not part of the scored record.
Current thesis
Borrowed sector re-rate has cooled: SLS closed $13.86 on 2026-09-04, 10.3% under the 2026-08-21 high of $15.46, RSI back to 54.1, while REGAL's last published count is still 78 of 80 from 2026-05-11 and BMF Capital's 2026-08-31 short report puts $3.50 on the other side. The name is now an undated binary with a maturing narrative and no company-dated catalyst before the 2026-09-25 AACR posters.
Kill line
A weekly close below $12.00 gives back the entire post-INTerpath-001 advance and returns price to the July range, under the 2026-08-14 pre-spike close of $12.78; secondarily, the 2026-09-25 AACR posters and both September FINRA short-interest reports passing with REGAL's event count still undisclosed.
Pick status
Invalidated resolved published kill line fired How this is scored →Latest analysis and events for SLS —
As of 20 September 2026, the latest FrontierPicks analysis for SELLAS Life Sciences Group, Inc. (SLS): Borrowed sector re-rate has cooled: SLS closed $13.86 on 2026-09-04, 10.3% under the 2026-08-21 high of $15.46, RSI back to 54.1, while REGAL's last published count is still 78 of 80 from 2026-05-11 and BMF Capital's 2026-08-31 short report puts $3.50 on the other side. The name is now an undated binary with a maturing narrative and no company-dated catalyst before the 2026-09-25 AACR posters.
Kill line: A weekly close below $12.00 gives back the entire post-INTerpath-001 advance and returns price to the July range, under the 2026-08-14 pre-spike close of $12.78; secondarily, the 2026-09-25 AACR posters and both September FINRA short-interest reports passing with REGAL's event count still undisclosed.
Next dated event on file: — catalyst in 5d.
Current Thesis
SELLAS Life Sciences’ cancer-vaccine re-rating thesis has broken its published price condition; REGAL’s survival results remain the unresolved clinical test. The week-ending 2026-09-18 reference close of $11.49 breached the $12.00 weekly threshold published on 2026-09-06. For that price-continuation leg, the narrative is dead — the September close establishes the structural failure, without establishing that the drug has failed.
The remaining clinical proposition concerns galinpepimut-S (GPS) in acute myeloid leukemia (AML). SELLAS’s 2026-08-11 update placed REGAL’s final analysis after the pre-specified 80th event and committed to announcing that event before database procedures and topline disclosure. It supplied no calendar date. This corrects the earlier coverage’s suggestion that there was no milestone-announcement commitment. SELLAS quarterly update.
Bullish and bearish views on SELLAS Life Sciences Group, Inc.
The model's bull view on SELLAS Life Sciences Group, Inc. (SLS), in brief: Company cash provides financial support. The bear view: The published structure has failed. The adjusted 2026-09-18 close was $11.49, below the previously published $12.00 weekly invalidation threshold. Moving that threshold lower would conceal the original thesis’s failure. Share issuance accompanied the funding. Common shares… Both cases follow in full.
Bull Case
- Company cash provides financial support. SELLAS reported approximately $138.3 million in cash and equivalents at 2026-06-30 and a $9.6 million net loss for that quarter. Those historical figures establish financial resources, not clinical efficacy or a guaranteed funding runway. 2026-08-11 results.
- A separate program has scheduled exposure. The company’s 2026-09-02 announcement identified three SLS009 preclinical pancreatic-cancer posters for 2026-09-25 through 2026-09-28. This supplies company-specific research content, although laboratory findings cannot settle REGAL’s survival endpoint. SELLAS poster announcement.
Bear Case
- The published structure has failed. The adjusted 2026-09-18 close was $11.49, below the previously published $12.00 weekly invalidation threshold. Moving that threshold lower would conceal the original thesis’s failure.
- Share issuance accompanied the funding. Common shares outstanding increased from 153,103,459 at 2025-12-31 to 201,918,874 at 2026-06-30. These balance-sheet figures establish dilution during that interval; they do not establish September issuance into strength. 2026-08-11 balance sheet.
- Conference evidence addresses another question. The 2026-09-02 poster announcement concerns preclinical pancreatic-cancer models involving SLS009. It contains no REGAL treatment-arm survival result. Company announcement.
Setup & Price Structure
Measured on 2026-09-18, SLS closed at $11.49, stood 25.7% below its $15.46 52-week high, and retained a three-month price increase of 34.7%. Its 14-period relative strength index (RSI) was 34.3. These supplied adjusted-bar measurements show residual medium-term appreciation alongside the breach; they do not establish a new support shelf.
Retail-oriented attention remains observable: Deepti Sri’s 2026-09-14 report paired SELLAS with ImmunityBio ahead of cancer conferences. That article establishes coverage, not the breadth of participation or a covering bid. The sample is too small to support a crowding claim, and September short interest remains unverified. September 14 coverage.
Catalyst Calendar (next 30 days)
- 2026-09-25: The American Association for Cancer Research (AACR) schedules publication of conference abstracts on this date. SELLAS’s 2026-09-02 announcement identifies its three accepted SLS009 posters. Publication makes the preclinical evidence inspectable; failure to publish those abstracts would invalidate this scheduled-disclosure expectation. AACR publication schedule.
- 2026-09-25 through 2026-09-28: AACR’s pancreatic-cancer conference is scheduled in San Diego. The company’s announced presentations concern SLS009, so this calendar window is not a dated REGAL efficacy decision. AACR conference, SELLAS announcement.
REGAL remains undated in the verified company disclosure of 2026-08-11. No specific day within this calendar window can be assigned to its outcome.
What Would Change Our Mind
The loss of the published continuation threshold is already observable: a weekly close below $12.00 occurred with the 2026-09-18 close of $11.49. A subsequent recovery would be new evidence and would not erase that recorded invalidation.
For the separate clinical proposition described in the 2026-08-11 update, a final REGAL release demonstrating statistically significant improvement on the primary overall-survival endpoint would support a new assessment. Failure on that endpoint would break the clinical proposition. The scheduled September SLS009 posters cannot substitute for that result.
Correlation Notes
The 2026-09-06 published note linked the August advance to Merck and Moderna’s 2026-08-19 INTerpath-001 melanoma announcement. That was a proposed sentiment connection between different therapies and indications, not measured evidence of correlated returns or transferable efficacy.
The 2026-09-14 article’s pairing of SELLAS and ImmunityBio similarly documents shared coverage only. No return series establishes a durable group relationship here; the clinical case remains a single-company binary tied to REGAL’s own outcome. September 14 coverage.
Notes
- REGAL is open-label and event-driven: topline can print on any session once the 80th event locks the database, with no pre-announcement obligation.
- Dilution channel is live: shares outstanding went 153,103,459 (2025-12-31) to 201,918,874 (2026-06-30) alongside the cash build to $138.3M.
- Single issuer with no approved product and 13 employees; a REGAL miss leaves SLS009 (Phase 2, 28 of 80 enrolled) as the only clinical asset of scale.
- 3D Medicines retains the exclusive Greater China GPS licence after the 2026-07-24 HKIAC ruling; the disputed $13.0M milestone claim was dismissed.
- Next scheduled company financial report is Q3 2026, around November; Q2 cleared 2026-08-11.
- Published short-interest readings for SLS currently conflict between roughly 55.0M shares and 29.34M shares; check FINRA's own file before using either.
Related · shared themes
APGE
Apogee Therapeutics, Inc.
Apogee Therapeutics’ $135.11-per-share cash-acquisition thesis resolved with AbbVie’s completion on 2026-09-03. The 2026-09-14 Form 15 advances administrative closure, leaving no unresolved APGE acquisition catalyst.
ATAI
AtaiBeckley Inc.
AtaiBeckley's Lilly acquisition thesis resolved with completion on 2026-09-11, ending the pending-merger case. Remaining contingent payments depend on disclosed clinical and regulatory milestones; Nasdaq suspended ATAI effective 2026-09-14.
PSNL
Personalis, Inc.
The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus two other suitors. Price broke to a $16.39 52-week high; Needham $17 and TD Cowen $18 now sit above the tape. Aug-4 Q2 is the next hard date.
RVMD
Revolution Medicines, Inc.
Regulatory-clock narrative re-accelerating: the rolling NDA under the FDA National Priority Voucher is "nearing completion" (2026-07-07) and the EMA opened a phased CHMP review the same day, while the Street ceiling walked from ~$186 to $235 (Guggenheim, 2026-07-09). The three-week digestion off the $192.62 high resolved higher on 2026-07-17 (+3.9% to $186.16) — the breakout retest the prior note wanted.
See also · stocks to watch